This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Drugs Medicine Protein 
Bio Pharma Dive
JANUARY 27, 2022
Backed by some of biotech's most powerful investors, Septerna is looking to usher in the next chapter of medicines that act on G protein-coupled receptors.
315 
Bio Pharma Dive
APRIL 25, 2023
Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the FDA to conditionally clear it for market.
351
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MARCH 7, 2023
Rapport Therapeutics aims to find new so-called receptor-associated proteins that could serve as targets for neurological disease medicines. Its most advanced drug is already in early-stage human testing.
362 
Pharmaceutical Technology
FEBRUARY 6, 2023
Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.
263 
Bio Pharma Dive
MARCH 11, 2024
Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.
281 
Bio Pharma Dive
MAY 18, 2021
The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.
338 
Bio Pharma Dive
OCTOBER 24, 2023
The startup is taking aim at an inflammation-linked protein known as TSLP, which is the target of an approved asthma medicine.
309 
Bio Pharma Dive
AUGUST 28, 2023
GPCRs, a ubiquitous family of proteins that are prime drug targets, have drawn the interest of companies like Structure Therapeutics, Septerna and now Superluminal Medicines.
246 
Bio Pharma Dive
OCTOBER 26, 2022
It joins a group of medicines on market that target a protein called BCMA. The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease.
294 
Pharmaceutical Technology
AUGUST 5, 2022
As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. It is ultra-rare,” says Jesús Rodriguez Requena, PhD, associate professor in the Department of Medicine at the University of Santiago de Compostela. No progress in drug discovery. “We
299 
Pharmaceutical Technology
JULY 7, 2022
But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Often referred to as a type of gene-modified cell therapy, CAR-T cell therapies involve genetically modifying a patient’s own T cells to produce a protein that enables them to identify and kill cancer cells.
245 
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 15, 2024
Twisted and tangled proteins are found in the brains of many of those who die with Alzheimer’s disease. Some scientists suspect these neural knots can harm and even kill brain cells, but so far in clinical trials, drugs that have tried to target the tangles have shown limited success. A promising new medicine has now […]
246 
Pharmaceutical Technology
JUNE 29, 2022
The pharmaceutical industry often relies on enzymes to perform a process known as biocatalysis, which facilitates the cost-effective and sustainable production of small molecule drugs at scale. The next wave of medicine is well on course to be cell and gene-based. Advantageous synergies within the Novo family make this a possibility.
295 
Worldwide Clinical Trials
JUNE 13, 2024
Pharmacogenomics (PGx), the study of how genes affect a person’s response to drugs, has brought significant changes to the clinical trial industry. This groundbreaking approach can help tailor medical treatments to an individual’s genetic makeup, considerably enhancing drug efficacy and safety while minimizing adverse drug reactions.
182 
Pharma Times
DECEMBER 20, 2023
Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. However, its relation to dopaminergic neuron death is unclear.
121 
Bio Pharma Dive
MAY 7, 2024
The company is using what it claims is the largest database of viral protein structures to unearth medicines for a range of diseases, said CEO and Flagship origination partner Lovisa Afzelius.
164 
Pharma Mirror
APRIL 21, 2024
With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.
130 
Pharmaceutical Technology
JANUARY 3, 2023
Blacksmith Medicines has signed a definitive merger agreement with Forge Therapeutics to create a combined entity that will discover and develop medicines targeting a large class of proteins called metalloenzymes. The merged entity will focus on developing medicines with an initial focus on oncology and infection.
130 
Pharmaceutical Technology
JULY 21, 2022
The company received fast-track designation from the US Food and Drug Administration (FDA) for the eltanexor development programme as a single agent to treat relapsed or refractory intermediate, high or very high-risk MDS patients. Eltanexor is a new oral selective inhibitor of nuclear export (SINE) compound.
264 
Pharma Times
JUNE 20, 2024
The progressive neurodegenerative condition affects more than ten million people worldwide
153 
Medical Xpress
NOVEMBER 8, 2022
Researchers at the University of Maryland School of Medicine's (UMSOM) Center for Precision Disease Modeling identified how a specific protein in SARS-CoV-2, the virus responsible for COVID-19, damages heart tissue. They then used a drug to reverse the toxic effects of that protein on the heart.
98 
Pharmaceutical Technology
NOVEMBER 11, 2022
The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.
246 
XTalks
DECEMBER 10, 2024
Rilzabrutinib works by targeting BTK, a protein involved in immune cell communication. By inhibiting this protein, the drug disrupts pathways that contribute to platelet destruction and insufficient production. percent platelet response in a study published in The New England Journal of Medicine.
104 
XTalks
MARCH 10, 2025
The FDA has approved Genentechs TNKase (tenecteplase) for the treatment of acute ischemic stroke in adults, marking a milestone as the first new stroke medicine approved in nearly three decades. TNKase works by initiating a biochemical reaction that breaks down fibrin, a protein that acts like the scaffolding holding blood clots together.
59 
Pharmaceutical Technology
DECEMBER 16, 2022
Novartis and the non-profit Medicines for Malaria Venture (MMV) announced plans to collaborate on a Phase III study of a novel ganaplacide/lumefantrine-SDF combination for adults and children. Both vaccines are based on recombinant proteins and attack the parasite during the sporozoite stage.
264 
Pharmaceutical Technology
SEPTEMBER 14, 2022
API peptides and proteins-based drugs have gained much attention in the past decade. Discover the top API protein and peptide companies in contract marketing. Technologies in the delivery of peptides and proteins. They are promising therapeutics for the treatment of a variety of metabolic and oncological disorders.
100 
Pharmaceutical Technology
APRIL 5, 2023
Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.
130 
Pharmaceutical Technology
APRIL 13, 2023
Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. With a silenced effector function, ALE.F02 has been designed for targeting the stiff ECM of fibrotic tissues and organs.
130 
XTalks
NOVEMBER 26, 2024
The US Food and Drug Administration (FDA) has approved Attruby (acoramidis) , marking a significant advancement for patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction.
105 
Scienmag
JUNE 10, 2022
PHILADELPHIA — A stress protein that is overactive in many types of tumor cells also has a key role in tumor-supporting cells called fibroblasts, and may be a good target for future cancer treatments, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.
83 
Pharmaceutical Technology
OCTOBER 18, 2022
A new study identifies a novel cerebrospinal fluid biomarker for Parkinson’s disease, expanding the scope of possible drug targets. In the Nature article, 76 CSF proteins were found to be structurally altered in individuals with PD relative to healthy individuals, identifying a new PD biomarker.
264 
Scienmag
FEBRUARY 18, 2022
CAMBRIDGE, MA — MIT chemists have discovered the structure of a protein that can pump toxic molecules out of bacterial cells. Proteins similar to this one, which is found in E. coli, are believed to help bacteria become resistant to multiple antibiotics.
82 
pharmaphorum
SEPTEMBER 14, 2020
Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. At that time, we thought this would be the holy grail for medicine. Now, however, the field is changing with respect to genomic medicine.
119 
XTalks
DECEMBER 12, 2023
Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.
111 
Pharmaceutical Technology
JUNE 28, 2022
grant from the National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) for developing a Covid-19 oral antiviral drug. The antiviral will be a low-dose drug which can be taken in the at-home setting. Those drugs that hinder only CLpro did not enhance the effects of remdesivir.
147 
XTalks
JANUARY 21, 2025
The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca. Datroway leverages DXd technology to precisely target cancer cells.
105 
Pharmaceutical Technology
JANUARY 4, 2023
The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted clearance for Transcenta’s investigational new drug (IND) application for its TST003 to treat solid tumours. The Gremlin1 protein was found to promote lineage plasticity while driving castration resistance in prostate cancer.
242 
XTalks
MARCH 31, 2023
BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.
97 
Pharmaceutical Technology
JANUARY 25, 2023
French biopharmaceutical firm Poxel has received orphan drug designation (ODD) from the European Commission (EC) for its molecules PXL770 and PXL065 to treat adrenoleukodystrophy (ALD). The latest move follows a positive opinion issued by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).
130 
Pharmaceutical Technology
DECEMBER 23, 2022
The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Sunlenca (lenacapavir) plus other antiretroviral(s) (ARV) to treat human immunodeficiency virus type 1 (HIV-1) infection. It acts by hindering the protein shell (capsid) of the HIV-1 virus to hamper the viral lifecycle’s steps.
147 
Scienmag
JULY 2, 2021
Studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers Credit: UC San Diego Health Sciences In cancer research, it’s a common goal to find something about cancer cells — some sort (..)
87 
pharmaphorum
JANUARY 12, 2023
Bayer has signed an agreement with Google aimed at using high-level processing power to handle quantum chemistry calculations used to predict the chemical and physical properties of drug molecules at the atomic scale. The post Bayer taps Google’s quantum power for drug discovery appeared first on. Image source: Google.
122
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content